Evidence map›Paper›PMID 26926910›Full record

Trial reportTrials2016

The clinical and cost effectiveness of cognitive behavioural therapy plus treatment as usual for the treatment of depression in advanced cancer (CanTalk): study protocol for a randomised controlled trial.

Marc Serfaty, Michael King, Irwin Nazareth, Adrian Tookman, John Wood, Anna Gola, Trefor Aspden, Kathryn Mannix, Sarah Davis, Stirling Moorey and 1 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Marc SerfatyDivision of Psychiatry, UCL, 6th Floor Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK. m.serfaty@ucl.ac.uk.
Michael KingDivision of Psychiatry, UCL, 6th Floor Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK. michael.king@ucl.ac.uk.
Irwin NazarethResearch Department of Primary Care & Population Health, UCL Royal Free Site, Rowland Hill Street, London, NW3 2PF, UK. i.nazareth@ucl.ac.uk.
Adrian TookmanMarie Curie Hospice, 11 Lyndhurst Gardens, London, NW3 5NS, UK. Adrian.Tookman@mariecurie.org.uk.
John WoodResearch Department of Primary Care & Population Health, UCL Royal Free Site, Rowland Hill Street, London, NW3 2PF, UK. i.nazareth@ucl.ac.uk.
Anna GolaMarie Curie Palliative Care Research Department, UCL, 6th Floor Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK. anna.gola@ucl.ac.uk.
Trefor AspdenDivision of Psychiatry, UCL, 6th Floor Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK. t.aspden@ucl.ac.uk.
Kathryn MannixPalliative Medicine, Newcastle upon Tyne Hospital NHS Foundation Trust, Freeman Road, Newcastle upon Tyne, NE7 7DN, UK. kathrynmannix@btinternet.com.
Sarah DavisMarie Curie Palliative Care Research Department, UCL, 6th Floor Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK. s.davis@ucl.ac.uk.
Stirling MooreyPsychotherapy and CBT, South London and Maudsley NHS Foundation Trust, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK. stirling.moorey@kcl.ac.uk.
Louise JonesMarie Curie Palliative Care Research Department, UCL, 6th Floor Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK. caroline.jones@ucl.ac.uk.
University College London · GBMarie Curie · GBKing's College London · GBMarie Curie Hospice · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBRoland Hill (United Kingdom) · GBThe Royal Free Hospital · GB

Funding

Department of Health 09/33/02Marie Curie MCCC-FCO-11-U
6 · The paper itself

Abstract

backgroundThe prevalence of depressive disorder in adults with advanced cancer is around 20 %. Although cognitive behavioural therapy (CBT) is recommended for depression and may be beneficial in depressed people with cancer, its use for depression in those with advanced disease for whom cure is not likely has not been explored.

methodsPeople aged 18 years and above with advanced cancer attending General Practitioner (GP), oncology or hospice outpatients from centres across England will be screened to establish a DSM-IV diagnosis of depression. Self-referral is also accepted. Eligible consenters will be randomised to a single blind, multicentre, randomised controlled trial of the addition to treatment as usual (TAU) of up to 12 one-hour weekly sessions of manualised CBT versus TAU alone. Sessions are delivered in primary care through Increasing Access to Psychological Care (IAPT) service, and the manual includes a focus on issues for people approaching the end of life. The main outcome is the Beck Depression Inventory-II (BDI-II). Subsidiary measures include the Patient Health Questionnaire, quality of life measure EQ-5D, Satisfaction with care, Eastern Cooperative Oncology Group-Performance Status and a modified Client Service Receipt Inventory. At 90 % power, we require 240 participants to enter the trial. Data will be analysed using multi-level (hierarchical) models for data collected at baseline, 6, 12, 18 and 24 weeks. Cost effectiveness analysis will incorporate costs related to the intervention to compare overall healthcare costs and QALYs between the treatment arms. We will conduct qualitative interviews after final follow-up on patient and therapist perspectives of the therapy. DISCUSSION: This trial will provide data on the clinical and cost effectiveness of CBT for people with advanced cancer and depression. We shall gain an understanding of the feasibility of delivering care to this group through IAPT. Our findings will provide evidence for policy-makers, commissioners and clinicians in cancer and palliative care, and in the community.

trial registrationControlled Trials ISRCTN07622709 , registered 15 July 2011.

Indexed as

Drug CostsAntidepressive AgentsClinical ProtocolsCognitive Behavioral TherapyCombined Modality TherapyCost-Benefit AnalysisEnglandHumansMajor Depressive DisorderNeoplasmsPsychiatric Status Rating ScalesQuality-Adjusted Life YearsQuality of LifeResearch DesignSingle-Blind MethodTime FactorsAntidepressive Agents

Identifiers

PMID26926910
PMCPMC4772591
OpenAlexW2292058387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.